Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system
DOI:
https://doi.org/10.11606/s1518-8787.2023057004280Keywords:
Arthritis, Rheumatoid, Delivery of Health Care, Public Expenditures, Biological Products, Pharmaceutical Services.Abstract
OBJECTIVE: This work aims to analyze the quantity and expenses related to biological drugs used for the treatment of rheumatoid arthritis (RA) in outpatient public care within the Brazilian Unified Health System (SUS). METHODS: It is a cross-sectional descriptive study based on secondary data from a historical series, referring to the purchase, volume, and the number of patients treated with different biological drugs (infliximabe, etanercept, adalimumab, rituximab, abatacept, tocilizumab, golimumab, and certolizumab pegol) for RA treatment in outpatient care from 2012 to 2017. The data were extracted from the SUS Outpatient Information System database-SIA/SUS and included ten drugs used for RA treatment. The study assessed the quantity and expenditure of these drugs, the number of RA patients treated, and the expenditure by RA subtypes. The National Broad Consumer Price Index was used to adjust the expenditures for December 2017. RESULTS: Th e M inistry o f H ealth a llocated approximately $ 500 m illion t o provide a bout 2 million units of biological drugs for RA patients from 2012 to 2017. The supply of adalimumab 40 mg and etanercept 50 mg accounted for 68.3% of the total expenditure. The subtypes “other rheumatoid arthritis with rheumatoid factor” (ICD-10 M05.8), “rheumatoid arthritis without rheumatoid factor” (ICD-10 M06.0), and “Felty’s syndrome” (M05. 0) represented 84.5% of the total expenditures. The proportion of patients treated with biological drugs increased by 33.0%. There was a significant 83.0% increase in the number of patients using biological drugs compared to the overall number of RA patients treated during the study period. CONCLUSIONS: The results obtained allow us to draw a more recent profile of expenditure on RA treatment and indicate trends in the use of biological drugs for this condition, generating data that can support management decisions in public health policies.
References
Ministério da Saúde (BR). Portaria Conjunta SAS/SCTIE No 15, de11 de dezembro de 2017. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatoide. Brasília, DF: Ministério da Saúde; 2017 [cited 2019 May 8]. Available from:
http://conitec.gov.br/images/Protocolos/PCDT_AR_2017_republicacao.pdf
Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology Criteria: a systematic review. Semin Arthritis and Rheum. 2006 Dec;36(3):182-8. https://doi.org/10.1016/j.semarthrit.2006.08.006
American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002 Feb;46(2):328-46. https://doi.org/10.1002/art.10148
Krishnan E, Lingala B, Bruce B, Fries JF. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis. 2012 Feb;71(2):213-8. https://doi.org/10.1136/annrheumdis-2011-200354
Carias CM, Vieira FS, Giordano CV, Zucchi P. Exceptional circumstance drug dispensing: history and expenditures of the Brazilian Ministry of Health. Rev Saúde Pública. 2011 Apr;45(2):233-40. https://doi.org/10.1590/S0034-89102011000200001
Silva GD, Andrade EIG, Cherchiglia ML, Almeida AM, Guerra Júnior AA, Acurcio FA. Perfil de gastos com o tratamento da Artrite Reumatoide para pacientes do Sistema Único de Saúde em Minas Gerais, Brasil, de 2008 a 2013. Cienc Saude Coletiva. 2018 Apr;23(4):1241-53. https://doi.org/10.1590/1413-81232018234.16352016
Azevedo AF, Petribú KCL, Lima MN, Silva AS, Rocha FIlho Ja, Mariano MHQA, et al. Quality of life of patients with rheumatoid arthritis under biological therapy. Rev Ass Med Bras. 2015 Mar-Apr, 2015;61(2):126-31. https://doi.org/10.1590/1806-9282.61.02.126
Oliveira Junior HA, Veiga TP, Acurcio FA., Almeida AM, Santos JBR, Silva MRR, et al. Impact of biologic DMARDs on quality of life:12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hosp Pract. 2020 Aug;48(4):213-22.
https://doi.org/10.1080/21548331.2020.1785212.
Gu T, Mutebi A, Stolshek BS, Tan H. Cost of biologic treatment persistence or switching in rheumatoid arthritis. Am J Manag Care. 2018 July;24(8 Spec No.):SP338-45.
Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, Herrinton LJ. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res. 2012 Nov;64(11):1649-56. https://doi.org/10.1002/acr.21755.
Buendgens FB, Blatt CR, Marasciulo AC, Leite SN, Farias MR. Estudo de custo-análise do tratamento da artrite reumatoide grave em um município do Sul do Brasil. Cad Saude Publica. 2013 Nov;29 Suppl 1:S81-91. https://doi.org/10.1590/0102-311X00013513
Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for inflation and currency changes within health economic studies. Value Health. 2019 Sep;22(9):1026-32. https://doi.org/10.1016/j.jval.2019.03.021
Exchange Rates UK. Brazilian Real (BRL) to US Dollar (USD) historical exchange rates on 31st December 2017 (31/12/17). 2020 [cited 2020 Jan 27]. Available from: https://www.exchangerates.org.uk/BRL-USD-31_12_2017-exchange-rate-history.html
Ministério da Saúde (BR). Departamento de Informática do SUS. DATASUS 2017 [cited 2020 Jun 7]. Available from: http://www2.datasus.gov.br/DATASUS/index.php?area=0901
Ministério da Saúde (BR). Portaria SAS/MS No 996, de 30 de setembro de 2015. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatoide. 2015 [cited 2019 May 20]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/sas/2015/ prt0996_30_09_2015.html
Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens AHM, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007 Nov;66(11):1443-9. https://doi.org/10.1136/ard.2007.071092.
Tundia N, Kotze PG, Rojas Serrano J, Abreu MM, Skup M, Macaulay D, et al. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia, and Mexico. J Medical Econom. 2016 Dec;19(12):1187-99. https://doi.org/10.1080/13696998.2016.1209508
Agência Nacional de Vigilância Sanitária. Anuário Estatístico do Mercado Farmacêutico-2017. Brasília, DF, 2018 [cited 2018 Nov 27]. Available from: http://portal.anvisa.gov.br/ documents/374947/3413536/Anu%C3%A1rio+Estat%C3%ADstico+do+Mercado+Farmac%C3%AAutico+-+2017/3179a522-1af4-4b4c-8014-cc25a90fb5a7
Vieira FS. Desafios do Estado quanto à incorporação de medicamentos no Sistema Único de Saúde. Brasília, DF: IPEA; 2019. (texto para Discussão, v. 44).
Schneiders RE. Caracterização dos gastos do Ministério da Saúde com medicamentos para artrite reumatoide, no âmbito do Componente Especializado da Assistência Farmacêutica, no período de 2008 a 2009. [Masters dissertation]. Brasília, DF: Universidade de Brasília; 2012.
Costa JO, Almeida AM, Guerra Junior AA, Cherchiglia ML, Andrade EIG, Acurcio FA. Tratamento da artrite reumatoide no Sistema Único de Saude, Brasil: gastos com infliximabe em comparacao com medicamentos modificadores do curso da doenca sinteticos, 2003 a 2006. Cad Saúde Pública. 2014 Feb;30(2):283-95. https://doi.org/10.1590/0102-311X00017913
Ministério da Saúde (BR). Portaria SAS/MS no 710, de 27 de junho de 2013. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatoide. 2013 [cited 2019 May 12]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/sas/2013/prt0710_27_06_2013.html
Ministério da Saúde (BR). Comissão Nacional de Incorporação de Tecnologias no SUS. Relatório de Recomendação no 12 da Comissão Nacional de Incorporação de Tecnologias no SUS. Medicamentos biológicos (Infliximabe, etanercept, adalimumabe, rituximabe, abatacepte, tocilizumabe, golimumabe e certolizumabe pegol) para o tratamento da Artrite Reumatoide. 2012 [cited 2019 May 23]. Available from: http://conitec.gov.br/images/Incorporados/Biologicos-ArtriteReumatoide-final.pdf
Ministério da Saúde (BR). Comissão Nacional de Incorporação de Tecnologias no SUS. Relatório de Recomendação no 654 da Comissão Nacional de Incorporação de Tecnologias no SUS. Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatoide. 2021 [cited 2019 May 23]. Available from http://conitec.gov.br/images/Relatorios/2021/20210910_Relatorio-Artrite_ Reumatoide_FINAL_654_2021.pdf
Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health. 2013 Mar;16(2):385-93. https://doi.org/10.1016/j.jval.2012.11.007
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Therap. 2001 Aug;23(8):1296-310. https://doi.org/10.1016/S0149-2918(01)80109-0
Madsen OR, Huynh TK, Østergaard A, Egsmose C. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014 Jan;8 :93-9. https://doi.org/10.2147/PPA.S55156
De Mits S, Lenaerts J, Vander Cruyssen B, Mielants H, Westhovens R, Durez P, et al. A nationwide survey on patients versus physician’s evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the be-raise study. PLoS One. 2016 Nov;11(11):e0166607. https://doi.org/10.1371/journal.pone.0166607
Published
Issue
Section
License
Copyright (c) 2023 Tacila Pires Mega, Rondineli Mendes da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
